117379-97-2

Usage

Uses

Used in Fragrance Industry:
Methyl 2-methyl-1-benzofuran-5-carboxylate serves as a fragrance ingredient, utilized in the production of perfumes, soaps, and cosmetics. Its floral and fruity scent makes it a valuable addition to these products, enhancing their appeal to consumers.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, methyl 2-methyl-1-benzofuran-5-carboxylate is employed as an intermediate in the synthesis of various drugs. Its chemical structure allows it to be a key component in the development of new medications.
Used in Organic Synthesis:
Methyl 2-methyl-1-benzofuran-5-carboxylate also has potential applications in the field of organic synthesis. Its unique properties make it a candidate for use in the creation of other organic compounds, contributing to the advancement of chemical research and development.
Used in Food Industry:
As a flavoring agent, methyl 2-methyl-1-benzofuran-5-carboxylate finds its way into food products, where it imparts its distinct flavor profile to enhance the taste and consumer experience.
Safety Precautions:
Due to its flammability and potential health hazards, methyl 2-methyl-1-benzofuran-5-carboxylate should be handled and stored with care to ensure the safety of individuals and the integrity of the compound.

Upstream product

• 98260-05-0 methyl 4-(2-propynoxy)benzoate 
• 64-18-6 formic acid 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 15804-76-9 3-(2-nitropropen-1-yl)-4-methoxybromobenzene 
• 1334637-58-9 C₁₁H₁₁ClO₃ 
• 205826-73-9 (5-Bromo-2-methoxyphenyl)acetone 
• 54965-04-7 5-bromo-2-methylbenzo[b]furan 
• 1761-61-1 5-bromosalicyclaldehyde 
• 67-56-1 methanol 
• 219763-06-1 2-Methyl-1-benzofuran-5-carboxylic acid 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 35750-24-4 methyl 4-allyloxybenzoate 

Downstream Products

• 219763-06-1 2-Methyl-1-benzofuran-5-carboxylic acid 
• 219764-11-1 3-(4-bromo-2-chlorobenzyl)-5-(methoxycarbonyl)-2-methylbenzo[b]furan 
• 219763-10-7 5-carboxy-3-(2,4-dichlorobenzyl)-2-methylbenzo[b]furan 
• 219764-14-4 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylbenzo[b]furan 
• 219763-17-4 5-carboxy-2-methyl-3-(4-phenylbenzyl)benzo[b]furan 
• 219764-13-3 5-carboxy-3-(2-chloro-4-phenylbenzyl)-2-methylbenzo[b]furan 

Relevant academic research and scientific papers

Enantio- and Diastereoselective, Complete Hydrogenation of Benzofurans by Cascade Catalysis

We report an enantio- and diastereoselective, complete hydrogenation of multiply substituted benzofurans in a one-pot cascade catalysis. The developed protocol facilitates the controlled installation of up to six new defined stereocenters and produces architecturally complex octahydrobenzofurans, prevalent in many bioactive molecules. A unique match of a chiral homogeneous ruthenium-N-heterocyclic carbene complex and an in situ activated rhodium catalyst from a complex precursor act in sequence to enable the presented process.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Cesium Fluoride-Mediated Claisen Rearrangements of Phenyl Propargyl Ethers: Effect of a Substituent on the Phenyl Ring on the Rearrangement

Methoxy or methoxycarbonyl-substituted phenyl propargyl ethers were subjected to Claisen rearrangement either in the absence or in the presence of CsF.Substituent effect on the cyclization is discussed.